---
title: "Essential Tremor"
description: "Clinical decision support for essential tremor diagnosis and management"
version: "1.0"
setting: "ED, HOSP, OPD"
status: approved
tags:
  - movement-disorders
  - tremor
  - outpatient
---

# Essential Tremor

**DIAGNOSIS:** Essential Tremor
**ICD-10:** G25.0 (Essential tremor)
**SCOPE:** Diagnosis confirmation, differentiation from Parkinson's disease and other tremors, and symptomatic treatment. Covers classic essential tremor and ET-plus syndrome.

**STATUS:** Approved

---

**PRIORITY KEY:** STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting

---

## SECTION A: ACTION ITEMS

---

## 1. LABORATORY WORKUP

### 1A. Essential/Core Labs

| Test | Rationale | Target Finding | ED | HOSP | OPD | ICU |
|------|-----------|----------------|:--:|:----:|:---:|:---:|
| TSH | Hyperthyroidism causes action tremor | Normal (0.4-4.0 mIU/L) | URGENT | ROUTINE | ROUTINE | - |
| Free T4 | If TSH abnormal | Normal | URGENT | ROUTINE | ROUTINE | - |
| BMP | Electrolyte abnormalities (hypomagnesemia) can cause tremor | Normal | STAT | ROUTINE | ROUTINE | - |
| Glucose | Hypoglycemia causes tremor | 70-180 mg/dL | STAT | ROUTINE | - | - |
| Hepatic panel | Hepatic encephalopathy can cause asterixis/tremor; baseline before medications | Normal | - | ROUTINE | ROUTINE | - |

### 1B. Extended Workup (Second-line)

| Test | Rationale | Target Finding | ED | HOSP | OPD | ICU |
|------|-----------|----------------|:--:|:----:|:---:|:---:|
| Magnesium | Hypomagnesemia causes tremor | 1.8-2.4 mg/dL | - | ROUTINE | ROUTINE | - |
| Ceruloplasmin, serum copper | Wilson's disease if age <50 | Normal | - | EXT | ROUTINE | - |
| 24-hour urine copper | Wilson's confirmation | <100 Î¼g/24hr | - | - | EXT | - |
| Drug/toxin screen | Caffeine, stimulants, alcohol withdrawal | Negative or explains tremor | STAT | ROUTINE | EXT | - |
| Vitamin B12 | Deficiency can cause tremor | >300 pg/mL | - | ROUTINE | ROUTINE | - |

### 1C. Rare/Specialized (Refractory or Atypical)

| Test | Rationale | Target Finding | ED | HOSP | OPD | ICU |
|------|-----------|----------------|:--:|:----:|:---:|:---:|
| Heavy metal panel (mercury, lead, arsenic) | Occupational exposure; toxin-induced tremor | Normal | - | - | EXT | - |
| Paraneoplastic antibody panel | Atypical tremor; occult malignancy | Negative | - | - | EXT | - |
| Anti-GAD65 antibodies | Stiff-person spectrum; autoimmune etiology | Negative | - | - | EXT | - |
| Genetic testing (LINGO1, SLC1A2) | Research; strong family history | Variable | - | - | EXT | - |

---

## 2. DIAGNOSTIC IMAGING & STUDIES

### 2A. Essential/First-line

| Study | Timing | Target Finding | Contraindications | ED | HOSP | OPD | ICU |
|-------|--------|----------------|-------------------|:--:|:----:|:---:|:---:|
| Clinical examination (spiral drawing, water pouring) | At evaluation | Symmetric action tremor; improves with alcohol; family history | None | STAT | ROUTINE | ROUTINE | - |

### 2B. Extended

| Study | Timing | Target Finding | Contraindications | ED | HOSP | OPD | ICU |
|-------|--------|----------------|-------------------|:--:|:----:|:---:|:---:|
| MRI Brain | Atypical features; focal signs; concern for structural lesion | Normal | MRI-incompatible devices | URGENT | ROUTINE | ROUTINE | - |
| DaTscan (ioflupane I-123) | Differentiate ET from Parkinson's disease | NORMAL in ET (abnormal in PD) | Iodine hypersensitivity | - | - | ROUTINE | - |
| EMG with accelerometry | Characterize tremor frequency (8-12 Hz typical ET) | 4-12 Hz, predominantly postural/kinetic | None | - | - | EXT | - |

### 2C. Rare/Specialized

| Study | Timing | Target Finding | Contraindications | ED | HOSP | OPD | ICU |
|-------|--------|----------------|-------------------|:--:|:----:|:---:|:---:|
| MRI Brain with SWI | Wilson's disease evaluation; iron deposition | No basal ganglia abnormalities | MRI contraindications | - | EXT | EXT | - |
| PET scan | Research; rule out neurodegenerative parkinsonian syndromes | Normal nigrostriatal pathway | None | - | - | EXT | - |
| Slit lamp examination | Wilson's disease (Kayser-Fleischer rings) | No KF rings | None | - | EXT | EXT | - |

---

## 3. TREATMENT

### 3A. Acute/Emergent

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| Propranolol (as needed) | PO | Situational tremor (performance anxiety, important meeting) | 20 mg PO; 40 mg PO :: PO :: :: 20-40 mg PO 30-60 min before anxiety-provoking situation; single dose PRN | Asthma; severe bradycardia; decompensated HF | HR, BP if first dose | URGENT | URGENT | ROUTINE | - |

### 3B. Symptomatic Treatments (First-line)

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| Propranolol | PO | First-line chronic therapy; most evidence | 20 mg BID; 40 mg BID; 60 mg BID; 80 mg BID; 120 mg daily LA; 160 mg daily LA :: PO :: :: Start 20 mg BID or 60 mg LA daily; titrate q2wk; target 60-240 mg/day | Asthma/COPD; bradycardia <50; heart block; decompensated HF | HR (>50 bpm), BP, fatigue, depression | - | ROUTINE | ROUTINE | - |
| Propranolol LA | PO | Once daily option for adherence | 60 mg daily; 80 mg daily; 120 mg daily; 160 mg daily :: PO :: :: Start 60-80 mg daily; titrate q2wk; max 320 mg/day | Same as IR | Same as IR | - | ROUTINE | ROUTINE | - |
| Primidone | PO | First-line; equal efficacy to propranolol | 25 mg qHS; 50 mg qHS; 50 mg TID; 125 mg TID; 250 mg TID :: PO :: :: Start 25 mg qHS (VERY LOW to avoid acute toxicity); increase by 25-50 mg q1wk; target 250-750 mg/day divided | Porphyria; severe hepatic impairment | Sedation (especially initial), ataxia, GI upset | - | ROUTINE | ROUTINE | - |
| Propranolol + Primidone | PO | Combination for better efficacy than monotherapy | Per individual drug :: PO :: :: Add second agent if monotherapy insufficient; use lower doses of each | Per individual drug | Monitor both sets of side effects | - | ROUTINE | ROUTINE | - |

### 3C. Second-line/Refractory

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| Topiramate | PO | Beta-blocker contraindicated; weight concern | 25 mg qHS; 50 mg BID; 100 mg BID :: PO :: :: Start 25 mg qHS; increase by 25 mg q1wk; target 100-400 mg/day divided | Glaucoma; kidney stones; pregnancy | Cognitive effects, paresthesias, weight loss, metabolic acidosis | - | ROUTINE | ROUTINE | - |
| Gabapentin | PO | Mild benefit; good tolerability; neuropathic pain comorbidity | 300 mg qHS; 300 mg TID; 600 mg TID; 900 mg TID :: PO :: :: Start 300 mg qHS; titrate by 300 mg q3-7d; target 1200-3600 mg/day divided TID | Severe renal impairment (dose adjust) | Sedation, dizziness, edema | - | ROUTINE | ROUTINE | - |
| Alprazolam | PO | Anxiolytic benefit; use with caution | 0.25 mg TID; 0.5 mg TID :: PO :: :: Start 0.25 mg TID; titrate slowly; max 3 mg/day; avoid long-term if possible | Respiratory depression; history of substance use | Dependence, sedation, falls | - | ROUTINE | ROUTINE | - |
| Clonazepam | PO | Orthostatic tremor; head tremor; refractory cases | 0.25 mg BID; 0.5 mg BID; 1 mg BID :: PO :: :: Start 0.25 mg BID; titrate slowly; typical 0.5-2 mg/day | Same as alprazolam | Same as alprazolam | - | ROUTINE | ROUTINE | - |
| Atenolol | PO | Beta-blocker alternative (more beta-1 selective) | 25 mg daily; 50 mg daily; 100 mg daily :: PO :: :: Start 25-50 mg daily; max 100 mg daily | Heart block; severe bradycardia | HR, BP | - | ROUTINE | ROUTINE | - |
| Nadolol | PO | Long-acting beta-blocker alternative | 40 mg daily; 80 mg daily; 120 mg daily :: PO :: :: Start 40 mg daily; titrate q1-2wk; max 240 mg daily | Same as propranolol | Same as propranolol | - | ROUTINE | ROUTINE | - |
| Sotalol | PO | Beta-blocker with additional antiarrhythmic properties | 80 mg BID; 120 mg BID :: PO :: :: Start 80 mg BID; max 240 mg/day; requires QTc monitoring | QT prolongation; severe renal impairment | QTc, electrolytes | - | ROUTINE | ROUTINE | - |
| Nimodipine | PO | Limited evidence; calcium channel blocker | 30 mg TID :: PO :: :: 30 mg TID | Hypotension | BP | - | - | EXT | - |
| Zonisamide | PO | Limited evidence; weight neutral | 100 mg daily; 200 mg daily :: PO :: :: Start 100 mg daily; may increase to 200 mg daily | Sulfonamide allergy; renal stones | Kidney stones, rash | - | - | EXT | - |

### 3D. Interventional/Advanced Therapies

| Treatment | Route | Indication | Dosing | Pre-Treatment Requirements | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|---------------------------|-------------------|------------|:--:|:----:|:---:|:---:|
| Botulinum toxin (head tremor) | IM | Head/neck tremor refractory to oral medications | 100-200 units total :: IM :: :: Inject into sternocleidomastoid and splenius capitis bilaterally; repeat q3-4mo | EMG guidance recommended | Infection at site; myasthenia gravis | Dysphagia, neck weakness | - | - | ROUTINE | - |
| Botulinum toxin (hand tremor) | IM | Hand tremor refractory to oral medications | 50-100 units per hand :: IM :: :: Inject into forearm flexors/extensors; EMG-guided; repeat q3mo | EMG guidance required | Same as above | Finger weakness (limits use) | - | - | ROUTINE | - |
| Deep brain stimulation (DBS) | Surgical | Medication-refractory disabling tremor | VIM thalamus stimulation :: Surgical :: :: Unilateral or bilateral VIM thalamus; programming over weeks | MRI; neuropsych testing; multidisciplinary evaluation | Cognitive impairment; unstable psychiatric disease; coagulopathy | Programming optimization; speech side effects (bilateral) | - | - | ROUTINE | - |
| MRI-guided focused ultrasound (MRgFUS) | Non-invasive | Unilateral tremor; DBS declined or contraindicated | VIM thalamotomy :: Non-invasive :: :: Unilateral lesion of VIM thalamus; immediate effect | Must tolerate prolonged MRI | Bilateral procedure not recommended (speech risk); skull density ratio | Numbness, ataxia, speech changes (usually transient) | - | - | ROUTINE | - |
| Gamma Knife radiosurgery | Non-invasive | VIM thalamotomy; DBS contraindicated | 130-150 Gy to VIM :: Non-invasive :: :: Unilateral lesion; delayed effect (months) | MRI compatible | Same as MRgFUS | Same as MRgFUS; delayed effect | - | - | EXT | - |

---

## 4. OTHER RECOMMENDATIONS

### 4A. Referrals & Consults

| Recommendation | ED | HOSP | OPD | ICU |
|----------------|:--:|:----:|:---:|:---:|
| Movement disorders neurology for diagnosis confirmation if uncertain and treatment optimization | - | ROUTINE | ROUTINE | - |
| Neurosurgery consultation for DBS or MRgFUS evaluation if medication-refractory | - | - | ROUTINE | - |
| Occupational therapy for adaptive devices and hand-writing strategies | - | - | ROUTINE | - |
| Physical therapy for postural training and coordination exercises | - | - | ROUTINE | - |
| Psychology/counseling for anxiety management and coping strategies | - | - | ROUTINE | - |

### 4B. Patient Instructions

| Recommendation | ED | HOSP | OPD |
|----------------|:--:|:----:|:---:|
| Avoid or minimize caffeine which can worsen tremor | - | ROUTINE | ROUTINE |
| Limit alcohol (may temporarily improve tremor but rebound worsening occurs and dependence risk) | - | ROUTINE | ROUTINE |
| Get adequate sleep as fatigue worsens tremor | - | ROUTINE | ROUTINE |
| Manage stress and anxiety which exacerbate tremor (relaxation techniques, regular exercise) | - | ROUTINE | ROUTINE |
| Use weighted utensils and adaptive devices for eating and writing if tremor interferes | - | ROUTINE | ROUTINE |
| Report any new symptoms such as slowness, stiffness, or balance problems which may indicate progression to ET-plus or Parkinson's | - | ROUTINE | ROUTINE |
| Consider alerting employer/school if tremor affects work performance to discuss accommodations | - | - | ROUTINE |

### 4C. Lifestyle & Prevention

| Recommendation | ED | HOSP | OPD |
|----------------|:--:|:----:|:---:|
| Regular physical exercise improves overall motor function and stress management | - | ROUTINE | ROUTINE |
| Relaxation techniques (yoga, meditation, deep breathing) reduce stress-related tremor exacerbation | - | - | ROUTINE |
| Avoid medications that worsen tremor (lithium, valproate, some antidepressants, stimulants) when alternatives exist | - | ROUTINE | ROUTINE |
| Use larger-grip pens and utensils to improve function | - | - | ROUTINE |
| Voice-to-text software if writing is significantly impaired | - | - | ROUTINE |
| Limit alcohol despite temporary improvement to avoid dependence and rebound tremor | - | ROUTINE | ROUTINE |

---

## SECTION B: REFERENCE

---

## 5. DIFFERENTIAL DIAGNOSIS

| Alternative Diagnosis | Key Distinguishing Features | Tests to Differentiate |
|-----------------------|----------------------------|------------------------|
| Parkinson's disease | Rest tremor predominant; bradykinesia; rigidity; asymmetric onset | DaTscan (abnormal in PD, normal in ET); clinical exam |
| Enhanced physiologic tremor | Typically bilateral, postural; related to caffeine, anxiety, medications, hyperthyroidism | Remove triggers; check TSH, caffeine history |
| Drug-induced tremor | Temporal relationship with medication; bilateral | Medication review; trial withdrawal |
| Dystonic tremor | Irregular, jerky; task-specific; associated dystonic posturing; null point | Clinical exam; may see dystonia at rest |
| Cerebellar tremor | Intention tremor (worsens at target); associated ataxia, dysarthria | MRI brain (cerebellar pathology); clinical exam |
| Psychogenic tremor | Variable frequency; distractible; entrainment with contralateral movement | Clinical maneuvers; psychiatric evaluation |
| Wilson's disease | Age <50; liver disease; psychiatric symptoms; Kayser-Fleischer rings | Ceruloplasmin, 24h urine copper, slit lamp |
| Orthostatic tremor | Tremor in legs/trunk when standing; relief with sitting/walking | EMG (13-18 Hz characteristic) |
| Rubral tremor | Rest + postural + intention ("Holmes tremor"); midbrain lesion history | MRI (midbrain pathology) |
| Neuropathic tremor | Associated with peripheral neuropathy (CIDP, IgM paraprotein) | EMG/NCS; protein electrophoresis |

---

## 6. MONITORING PARAMETERS

| Parameter | Frequency | Target/Threshold | Action if Abnormal | ED | HOSP | OPD | ICU |
|-----------|-----------|------------------|-------------------|:--:|:----:|:---:|:---:|
| Tremor severity (clinical rating scales: Fahn-Tolosa-Marin, TETRAS) | Each visit | 50%+ improvement with treatment | Adjust medication dose; consider second agent or intervention | - | ROUTINE | ROUTINE | - |
| Functional impact (writing, eating, drinking) | Each visit | Acceptable function for patient | OT referral; adaptive devices; consider advanced therapy | - | ROUTINE | ROUTINE | - |
| Heart rate (if on beta-blocker) | Each visit | >50 bpm | Reduce dose or switch agent | - | ROUTINE | ROUTINE | - |
| Blood pressure (if on beta-blocker) | Each visit | >90/60 | Reduce dose or switch agent | - | ROUTINE | ROUTINE | - |
| Sedation/cognition (if on primidone or benzodiazepines) | Each visit | Tolerable side effects | Reduce dose; slow titration | - | ROUTINE | ROUTINE | - |
| Signs of parkinsonism | Each visit | No bradykinesia, rigidity, rest tremor | Re-evaluate diagnosis; DaTscan if uncertain | - | ROUTINE | ROUTINE | - |
| Weight (if on topiramate) | Every 3 months | Stable or acceptable change | Adjust dose | - | - | ROUTINE | - |
| QTc (if on sotalol) | Baseline, with dose changes | <500 msec | Reduce dose or discontinue | - | ROUTINE | ROUTINE | - |

---

## 7. DISPOSITION CRITERIA

| Disposition | Criteria |
|-------------|----------|
| Discharge home | New diagnosis with treatment started; follow-up arranged; no red flags |
| Admit to floor | Rare; only if tremor is severe and workup needed urgently (e.g., Wilson's disease suspected) |
| Outpatient follow-up | 4-8 weeks for medication titration; then every 6-12 months when stable |

---

## 8. EVIDENCE & REFERENCES

| Recommendation | Evidence Level | Source |
|----------------|----------------|--------|
| Propranolol first-line for ET | Class I, Level A | [Zesiewicz et al. Neurology 2011 (AAN Guideline)](https://pubmed.ncbi.nlm.nih.gov/22013182/) |
| Primidone first-line for ET | Class I, Level A | [Zesiewicz et al. Neurology 2011](https://pubmed.ncbi.nlm.nih.gov/22013182/) |
| Topiramate effective for ET | Class II, Level B | [Ondo et al. Neurology 2006](https://pubmed.ncbi.nlm.nih.gov/16636234/) |
| DBS effective for medication-refractory ET | Class I, Level A | [Flora et al. Cochrane 2010](https://pubmed.ncbi.nlm.nih.gov/20927732/) |
| MRI-guided focused ultrasound for ET | Class I, Level A | [Elias et al. NEJM 2016](https://pubmed.ncbi.nlm.nih.gov/27557301/) |
| DaTscan differentiates ET from PD | Class II, Level B | [Benamer et al. Mov Disord 2000](https://pubmed.ncbi.nlm.nih.gov/10752577/) |
| Botulinum toxin for head tremor | Class II, Level B | [Pahwa et al. Neurology 1995](https://pubmed.ncbi.nlm.nih.gov/7617193/) |
| Gabapentin modest benefit | Class II, Level U | [Ondo et al. Neurology 2000](https://pubmed.ncbi.nlm.nih.gov/10680798/) |
| Combination therapy superior to monotherapy | Class II, Level B | [Koller et al. Neurology 1989](https://pubmed.ncbi.nlm.nih.gov/2668781/) |

---

## CHANGE LOG

**v1.0 (January 27, 2026)**
- Initial template creation
- Comprehensive medication coverage including first and second-line options
- Includes advanced interventions (DBS, MRgFUS, Gamma Knife)
- Structured dosing format for order sentence generation
